Stay updated on Pembrolizumab + Ipilimumab vs. Placebo in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab + Ipilimumab vs. Placebo in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab + Ipilimumab vs. Placebo in NSCLC Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    Revision tag updated from v3.3.3 to v3.3.4 on the page. This is a routine version label change.
    Difference
    0.0%
    Check dated 2026-01-16T04:47:02.000Z thumbnail image
  2. Check
    10 days ago
    No Change Detected
  3. Check
    17 days ago
    No Change Detected
  4. Check
    25 days ago
    No Change Detected
  5. Check
    32 days ago
    Change Detected
    Summary
    A centralized Locations section was added, enumerating study sites across many countries, and several regional location blocks were removed.
    Difference
    2%
    Check dated 2025-12-17T17:52:41.000Z thumbnail image
  6. Check
    54 days ago
    Change Detected
    Summary
    Publication section wording updated to clarify auto-population from PubMed and potential non-relations to the study. Page revision tag updated to Revision: v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2025-11-26T07:30:12.000Z thumbnail image
  7. Check
    61 days ago
    Change Detected
    Summary
    The page no longer displays the generic government funding status notice. This change does not affect the study details, eligibility criteria, or results information.
    Difference
    0.1%
    Check dated 2025-11-19T08:21:36.000Z thumbnail image
  8. Check
    68 days ago
    Change Detected
    Summary
    In the Taiwan location entry, 'Tainan City, Taiwan, 70457' was changed to 'Tainan, Taiwan, 70457'.
    Difference
    0.0%
    Check dated 2025-11-12T00:17:36.000Z thumbnail image
  9. Check
    83 days ago
    Change Detected
    Summary
    No additions or deletions were detected on the Study Details page for NCT03302234; the content appears unchanged between the two screenshots. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2025-10-28T05:17:19.000Z thumbnail image

Stay in the know with updates to Pembrolizumab + Ipilimumab vs. Placebo in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Ipilimumab vs. Placebo in NSCLC Clinical Trial page.